Compare BLD & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLD | IONS |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 13.5B |
| IPO Year | N/A | 1991 |
| Metric | BLD | IONS |
|---|---|---|
| Price | $550.90 | $80.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 22 |
| Target Price | ★ $444.14 | $84.09 |
| AVG Volume (30 Days) | 285.3K | ★ 2.3M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 19.67 | N/A |
| Revenue | ★ $5,236,045,000.00 | $966,957,000.00 |
| Revenue This Year | $2.61 | $29.79 |
| Revenue Next Year | $13.86 | $0.46 |
| P/E Ratio | $28.01 | ★ N/A |
| Revenue Growth | N/A | ★ 20.41 |
| 52 Week Low | $266.26 | $23.95 |
| 52 Week High | $555.85 | $86.74 |
| Indicator | BLD | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 72.31 | 45.60 |
| Support Level | $521.03 | $82.55 |
| Resistance Level | $555.85 | $84.96 |
| Average True Range (ATR) | 18.20 | 2.32 |
| MACD | 5.16 | -0.30 |
| Stochastic Oscillator | 94.78 | 11.78 |
TopBuild Corp is an installer and distributor of insulation products. Its operating segments involve the Installation and Specialty Distribution segment. The installation segment provides insulation installation services nationwide through contractor services business. Speciality Distribution segment distributes building and mechanical insulation, insulation accessories and other building product materials for the residential, commercial, and industrial end markets. The majority of revenue is earned from the installation segment. Its main customers are contractors. Other products include gutters, after-paint, garage doors, fireplaces, and fireproofing and stopping. TopBuild operates majorly in the United States.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.